Gonadotropin-releasing hormone agonists for the preservation of ovarian function during chemotherapy

Journal of Clinical Oncology

Volumn 30, Issue 26, 2012, Pages 3310-3311

  Tomao, Federica ^a   Panici, Pierluigi Benedetti ^a   Tomao, Silverio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; GONADORELIN AGONIST; GOSERELIN; INHIBIN A; INHIBIN B;

ADJUVANT CHEMOTHERAPY; AMENORRHEA; BREAST CANCER; CANCER RADIOTHERAPY; FEMALE FERTILITY; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; HUMAN; LETTER; MENSTRUATION; OVARIAN PRESERVATION; OVARY FUNCTION; OVARY INSUFFICIENCY; PRIORITY JOURNAL;

EID: 84866548226     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.2436     Document Type: Letter

References (7)

1. Munster PN, Moore AP, Ismail-Khan R, et al: Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 30:533-538, 2012
2. Partridge AH: Ovarian suppression for prevention of premature menopause and infertility: Empty promise or effective therapy? J Clin Oncol 30:497-481, 2012
3. Recchia F, Saggio G, Amiconi G, et al: Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 106:514-523, 2006 (Pubitemid 43157613)
4. Del Mastro L, Boni L, Michelotti A, et al: Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: A randomized trial. JAMA 306:269-276, 2011
5. Gerber B, von Minckwitz G, Stehle H, et al: Effect of luteinizing hormone releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: The GBG 37 ZORO study. J Clin Oncol 29:2334-2341, 2011
6. Del Mastro L: Temporary ovarian suppression with goserelin and ovarian function protection in patients with breast cancer undergoing chemotherapy. J Clin Oncol 29:3339-3340; author reply 3341-3342, 2011
7. Anderson RA, Nelson SM, Wallace WH: Measuring anti-Müllerian hormone for the assessment of ovarian reserve: When and for whom is it indicated? Maturitas 71:28-33, 2012